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and endothelial dysfunction after ischemia-reperfusion
and cardiopulmonary bypass (CPB). Complement acti-
vation as a consequence of exposure of blood compo-
C omplement activation, polymorphonuclear leuko-cytes (PMNs), and increased circulating levels of
various cytokines are 3 major causes of tissue damage
Objective: Because C5a induces tissue injury by activating polymor-
phonuclear leukocytes, the hypothesis was that inhibition of C5a activity
would reduce cardioplegia-related injury. Methods: Pigs were placed on
cardiopulmonary bypass. The hearts were arrested for 1 hour with
hyperkalemic cardioplegia. Pigs were then separated from bypass, and
the hearts were reperfused for 2 hours. Anti-porcine C5a monoclonal
antibody (1.6 mg/kg, intravenously; n = 6) was administered 20 minutes
before the onset of cardiopulmonary bypass. Six pigs received saline
solution vehicle. Reactivity of coronary arterioles was studied in vitro
with videomicroscopy. Microvessels from uninstrumented pigs served as
controls for vascular studies. Results: Endothelium-dependent relaxation
to adenosine diphosphate (percent relaxation of precontraction) was
reduced after cardioplegic reperfusion (63% ± 14% vs 77% ± 10% in
control at 10 m mol/L; P = .01). This impairment in endothelium-depen-
dent relaxation was improved with anti-porcine C5a monoclonal anti-
body (80% ± 22%; P = .01 vs saline solution), as was the impaired
endothelium-dependent relaxation to clonidine (64% ± 12% control;
26% ± 17% saline solution; 55% ± 24% anti-porcine C5a monoclonal
antibody at 10 m mol/L; P = .01 saline solution vs control or anti-porcine
C5a monoclonal antibody). Myeloperoxidase activity was significantly
decreased (0.2 ± 0.2 units/g protein; P = .04) in the anti-porcine C5a
monoclonal antibody group compared with 5.2 ± 2.7 in the saline solu-
tion group. CH50 2 hours after bypass was not statistically different (0.57
± 0.41 unit and 0.65 ± 0.41 unit, respectively) between the anti-porcine
C5a monoclonal antibody and saline solution groups. Despite less
myocardial polymorphonuclear leukocyte infiltration after C5a inhibi-
tion, maximum rate of rise of left ventricular pressure, percent segmen-
tal shortening, and blood flow through the left anterior descending coro-
nary artery were similar in the anti-porcine C5a monoclonal antibody
and saline solution groups. Conclusions: Inhibition of C5a limits neu-
trophil-mediated impairment of endothelium-dependent relaxation
after cardiopulmonary bypass and cardioplegic reperfusion, but it has
no effect on short-term myocardial functional preservation. (J Thorac
Cardiovasc Surg 1998;116:1060-8)
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nents to the CPB circuit occurs through both the classi-
cal and alternative pathways.1-5
The complement fragments C3a, C5a, and C5b-9 all
gradually increase in concentration after the initiation
of CPB and play a major role in mediating the systemic
inflammatory response observed during and after CPB.
C5a and C5b-9 may directly activate PMNs6,7 and
induce increased expression of the P-selectin and other
adhesion molecules on endothelial cell sufaces.8,9
Deposition of C5b-9 can be observed on endothelial
cells soon after the initiation of reperfusion10 and can
directly attenuate endothelium-dependent relaxation.11
In this regard, Rinder and associates12 using an in vitro
model, have recently reported that an anti-human C5
monoclonal antibody blocks cleavage of C5 and effec-
tively attenuates leukocyte activation during CPB.
However, specific inhibition of C5a has not been fully
tested in a clinically relevant model of CPB and car-
dioplegia-reperfusion.
In this study, we assessed the efficacy of a mono-
clonal antibody to C5a in modulating neutrophil
chemotaxis and aggregation and complement-mediated
hemolysis. Then we used an in vivo porcine model of
CPB and cardioplegia-reperfusion to determine the role
of C5a-mediating coronary microvascular endothelial
dysfunction, myocardial neutrophil infiltration, sys-
temic complement activation, myocardial edema for-
mation, and possible altered expression of the inducible
(iNOS) and constitutive (cNOS) isoforms of nitric
oxide synthase.
Methods
Hybridoma and antibody production/purification.
Female Balb-C mice were immunized with 25 m g of purified
porcine C5a (pC5a) with standard techniques. Mice received
boosters monthly with 25 m g of purified pC5a for 3 months.
The mice were killed 5 days after intravenous injection of 1
m g of pC5a. Fusion of splenocytes with the P3/NSI/1-Ag4-1
mouse myeloma cell line was done by standard techniques.
Hybridomas were screened by an antibody-capture enzyme-
linked immunosorbent assay (ELISA) with 96-well plates
coated with pC5a. Limiting dilution techniques were used to
isolate a single positive clone. GS17F1C4 (GS1) was isolated
as a murine IgG1k isotype. Antibodies were produced in tis-
sue culture and as ascites. Purification of the antibody was
achieved by protein G column chromatography with glycine
(100 mmol/L; pH 3.0) as the elutant. 
Porcine PMN purification, chemotaxis, and aggregation
studies. Porcine PMN aggregation and chemotaxis studies
were performed as we have previously described.13,14
Zymosan-activated porcine sera (PAS; 10 m L) was used as the
chemotactic agent. GS1 (0 to 51 m g/mL) was added to the
PAS for 30 minutes before application to the chemotaxis
wells.
Animal preparation. Yorkshire pigs (20 to 25 kg) of either
sex were premedicated with ketamine (10 mg/kg, intramus-
cularly) and anesthetized with a -chloralose and urethane (60
mg/kg and 300 mg/kg intravenously initially and then 15
mg/kg and 60 mg/kg every 60 minutes as needed, respective-
ly). Pigs were intubated and mechanically ventilated
(Harvard Apparatus Inc, South Natick, Mass). In the control
group (n = 6), a sternotomy was performed, and the pigs were
heparinized (500 units/kg). The hearts were rapidly excised
and immediately placed in a cold (4°C to 10°C) Krebs buffer
solution of the following composition (in millimolars): 118.3
NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 NaH2PO4, 25.0
NaHCO3, and 11.1 glucose.
In 12 pigs, after the induction of anesthesia and tracheal
intubation, fluid-filled catheters were introduced into the
femoral artery for the measurement of peripheral arterial
pressure. After a sternotomy was performed, purse-string
sutures were placed in the distal ascending aorta and the right
atrium. Instantaneous left anterior descending coronary
artery (LAD) blood flow was measured with a 2.5-mm ultra-
sonic transit-time flow probe (model 2.5S; Transonic System
Inc, Ithaca, NY) that was placed around the LAD distal to the
second diagonal branch. The flow probe was connected to a
flow monitor (model T206; Transonic System Inc). A pair of
ultrasonic crystals was implanted 10 to 15 mm apart and
approximately 3 mm beneath the surface of the left ventricu-
lar subepicardium. The crystals were placed parallel to the
long axis of the left ventricle. An 8F micromanometer-tipped
catheter (model SPC-370; Millar Instruments, Houston, Tex)
was placed in the left ventricle through the apex for the mea-
surement of left ventricular systolic pressure (LVSP) and rate
of change of LV pressure (LV dP/dt). LV dP/dt, the first deriv-
ative of LV pressure, was derived by differentiating the left
ventricular pressure signal over time. Six pigs were random-
ized to receive anti-C5a monoclonal antibody (GS1; 1.6
mg/kg) intravenously 20 minutes before the onset of CPB.
Six pigs received saline solution vehicle alone. Pigs were
given heparin (500 units/kg) and cannulated via the distal
ascending aorta and the right atrium through the purse-string
sutures. Activated clotting time was maintained for more than
400 seconds. A left ventricular vent was placed via the left
ventricular apex for decompression. A small cannula was
inserted into the ascending aorta through another purse-string
suture for the infusion of cardioplegic solution. Normo-
thermic CPB was instituted with a bubble oxygenator
(Bentley Bio-2; Baxter Healthcare Corp, Irvine, Calif) and a
standard roller pump. An arterial filter (Bentley Bio-1025;
Baxter Healthcare Corp) was inserted into the circuit distal to
the roller pump. Blood flow was maintained from 2.0 to 3.0
L/min (2.6 to 4.2 L/min/m2) to maintain a mean perfusion
pressure of 40 to 70 mm Hg. Systemic blood temperature was
maintained at 37°C during the entire study. Arterial blood
gases were obtained (model 1306, pH/Blood Gas Analyzer;
Instrumentation Laboratory, Lexington, Mass) before CPB
was begun and at approximately 15-minute intervals there-
after. Arterial blood gases were adjusted by ventilatory rate
and tidal volume to maintain PaO2 more than 50 mm Hg, PCO2
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more than 30 and less than 45 mm Hg, and pH between 7.30
and 7.45. After stabilization of the preparation for CPB, an
aortic crossclamp was placed and 300 mL of a cold (0°C to
4°C) hyperkalemic crystalloid cardioplegic solution was
infused into the aortic root at a pressure of 60 mm Hg. The
composition of hyperkalemic crystalloid cardioplegic solu-
tion was (in millimoles per liter): 121 NaCl, 25 KCl, 12
NaHCO3, 11.1 glucose, in purified water. Saline solution
slush was placed on the surface of the heart to provide topi-
cal hypothermia during the crossclamp period. Myocardial
temperature in the distribution of LAD was measured with a
probe and ranged from 4°C to 10°C during the ischemic peri-
od. Infusion of the cardioplegic solution (150 mL) was
repeated at 20-minute intervals for 60 minutes (2 additional
doses). The aortic crossclamp was removed after 60 minutes
of cardioplegic arrest, and the heart was reperfused with nor-
mothermic blood from the bypass circuit. The heart was kept
decompressed with a left ventricular vent until a stable
rhythm was obtained. Attempts were made to maintain the
mean reperfusion pressure between 40 and 70 mm Hg. In the
event of ventricular fibrillation, lidocaine (10 mg) was in-
fused intravenously, and the heart was defibrillated with 10 J
after the myocardial temperature rose to greater than 30°C.
Pigs were weaned from CPB and decannulated. Heparin was
not reversed with protamine. After 120 minutes of reperfu-
sion, the heart was rapidly excised and immediately placed in
a cold Krebs buffer solution or in liquid nitrogen. 
All animals received humane care in compliance with the
Beth Israel Deaconess Medical Center Animal Care and Use
Committee and the National Research Council’s “Guide for
the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animals and published by the
National Institutes of Health (NIH Publication No. 86-23,
revised 1985).
Hemodynamic measurements. The following parameters
were measured every 30 minutes: LAD blood flow, mean
peripheral arterial pressure (MAP), LVSP, LV maximum dP/dt
(LV max dP/dt), and percent segmental shortening. Percent
segmental shortening was calculated as follows: 100 · (end-
diastolic segment length—end-systolic segment length)/end-
diastolic segment length, where end-diastolic segment length
was measured at the onset of LV dP/dt and end-systolic seg-
ment length was measured at peak negative LV dP/dt.
Measurement of GS1 antibody in porcine plasma.
Murine antibody concentrations were measured in porcine
plasma collected at various times during the course of the
CPB procedure as described before with modifications.15
Briefly, 50 m L of a polyclonal antibody to murine IgG (2
m g/mL in sodium carbonate buffer) was placed in each well
of a 96-well microtiter plate and incubated overnight at 4°C.
The plate was washed and blocked with 3% bovine serum
albumin for 2 hours at room temperature. The plates were
then washed, covered, and placed at –20°C until used for the
ELISA. Known amounts of murine IgG antibody were used
to generate a standard curve from 10 m g/mL to 1 ng/mL.
Unknown pig plasma samples were diluted 1:40 with Hanks’
balanced salt buffer and run in duplicate on the ELISA plates.
After the plates were washed, a goat polyclonal anti-murine
IgG antibody conjugated with horseradish peroxidase was
added and incubated for 1 hour at room temperature. The
plate was washed and then developed with 2,2´azino-bis(3-
ethylbenzthiol) sulfonic acid and read on a plate reader
(Molecular Devices, Sunnyvale, Calif).
Microvascular preparation. Arterial microvessels (60 to
180 µm, internal diameter) were dissected from the LAD-
dependent subepicardial region in the left ventricle (stored in
cold Krebs buffer) with a · 10 to · 60 dissecting microscope
(Olympus Optical, Tokyo, Japan) within 6 hours of comple-
tion of the animal experiment. Microvessels were placed in a
microvessel chamber (University of Iowa Medical Instru-
mentation, Iowa City, Iowa), cannulated with dual glass
micropipettes measuring 40 to 80 µm in diameter, and
secured with 10-0 nylon monofilament suture (Ethicon, Inc,
Somerville, NJ). Oxygenated (95% oxygen/5% carbon diox-
ide) Krebs buffer solution warmed to 37°C was continuously
circulated through the organ chamber. The vessels were pres-
surized to 40 mm Hg in a no-flow state with a burette
manometer filled with a Krebs buffer solution. With an in-
verted microscope (· 40 to · 200, Olympus CK2; Olympus
Optical) connected to a video camera, the vessel image was
projected onto a black-and-white television monitor. An elec-
tronic dimension analyzer (Living System Instrumentation,
Burlington, Vt) was used to measure internal lumen diameter.
Measurements were recorded (Graphtec, Irvine, Calif). Ves-
sels were allowed to bathe in the organ chamber for at least
30 minutes before an intervention.
Microvessel study protocols. In all experimental groups,
relaxation responses of microvessels were examined after
precontraction of coronary microvessels with acetylcholine
chloride by 20% to 70%. Once the steady-state tone was
reached, the dose responses of the coronary microvessels to
adenosine 5´-diphosphate (ADP; receptor-mediated endothe-
lium-dependent vasodilators 10–9 to 10–4 mol/L) and cloni-
dine hydrochloride (a 2-adrenoceptor agonist, 10–9 to 10–5
mol/L), and the endothelium-independent vasodilators sodi-
um nitroprusside (endothelium-independent vasodilator, 10–9
to 10–4 mol/L) and isoproterenol (b -adrenoceptor agonist,
10–12 to 10–6 mol/L) were examined. Measurements were
made and recorded 2 to 3 minutes after the drug was admin-
istered, when the response had stabilized. All drugs were
applied extraluminally. One to 4 interventions were per-
formed on each vessel. The order of the drug administration
was random. The vessels were washed with a Krebs buffer
solution and allowed to equilibrate in a drug-free Krebs
buffer solution for 15 to 30 minutes between interventions. 
Amplification and quantitation of cNOS and iNOS
cDNA fragment by reverse transcriptase–polymerase
chain reaction. To examine myocardial mRNA of the cNOS
and the iNOS, reverse transcriptase–polymerase chain reac-
tion (RT-PCR) was performed. cNOS and iNOS fragments
were amplified by RT-PCR from myocardium stored in liquid
nitrogen. Primers were designed based on the published
cNOS16 and iNOS sequence.17 The primers of the sense 5´-
AGACCCCTGGAAAGGGAG-3´ corresponding to bases
1443-1460 and the antisense 5´-TGTGTTACTGGATTC-
CTTCC-3´ corresponding to bases 1901-1920 were used to
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amplify a 486–base pair fragment of cNOS.16 For iNOS, the
primer of sense 5´-GCCTCGCTCTGGAAAGA-3´ corre-
sponding to bases 1425-1441 and the antisense 5´-TCCAT-
GCAGACAACCTT-3´ corresponding to bases 1908-1924
were used to amplify a 500–base pair fragment of cNOS.17
An equal amount of total RNA was used for RT-PCR from
control and experimental groups. For quantification, glycer-
aldehyde-3-phosphate dehydrogenase was amplified from the
same amount of RNA to correct for variation of different
samples. The PCR products were loaded in 1.5% agarose gel,
scanned, and measured on an Image-Quant software
(Molecular Dynamics, Sunnyvale, Calif). 
Myocardial myeloperoxidase activity. Tissue samples
from the left ventricle were excised at the end of reperfusion,
frozen in liquid nitrogen, and stored at –80°C until assayed.
Myeloperoxidase activity was measured as Amsterdam and
associates18 previously described. Ice-cold, minced sections of
the tissues were homogenized (10% wt/vol) with a Polytron
homogenizer (Brinkmann Instruments, Westbury, NY) in 50
mmol/L phosphate buffer solution (pH 6.0) containing 0.5%
hexadecyltrimethyl-ammonium bromide for 15 seconds twice.
The homogenates were then sonicated for 15 seconds, and the
supernatant containing the myeloperoxidase enzyme was sepa-
rated from the cellular debris by centrifugation at 20,000g for
15 minutes (2°C). The appearance of a colored product from
the myeloperoxidase-dependent reaction of o-dianisidine and
hydrogen peroxide (0.0005%) was spectrophotometrically
detected with 100 mL of supernatant, 1.9 mL of hydrogen per-
oxide, and o-dianisidine in 50 mmol/L phosphate buffer solu-
tion (pH = 6.0). Supernatant myeloperoxidase activity was
kinetically quantified on a temperature-controlled (25°C) spec-
trophotometer. The absorbance at 460 nm was recorded for
several minutes, and the change in absorbance over 1 minute
was measured during the linear portion (0.5 to 1.5 minute) of
the tracing. One unit of myeloperoxidase activity was defined
as that which degraded 1 mol hydrogen peroxide/minute at
25°C. Assessment of this assay with isolated porcine neu-
trophils demonstrated a linear relationship (r = 0.92) between
myeloperoxidase and the number of cells, such that 1 unit of
myeloperoxidase activity correlated with 2.9 · 106 neutrophils.
Fig 1. Effect of GS1 on porcine C5a-induced porcine PMN
aggregation. GS1 dose dependently attenuated pC5a-induced
PMN aggregation. The data represent means ± SEM of 7
independent experiments. Fig 2. Effect of GS1 on zymosan-activated porcine sera
(PAS)-induced chemotaxis of porcine PMN. GS1 dose-depen-
dently attenuated PAS-induced PMN chemotaxis. GS1 (17
mg/mL) significantly inhibited PAS-induced chemotaxis com-
pared with untreated PAS. Chemotaxis induced by normal pig
sera (PS) treated with GS1 was not significantly different from
PAS treated with GS1 (17 or 51 mg/mL). The data represent
means ± SEM of 6 independent experiments. *P < .05 vs 0
concentration.
Fig 3. Hemolytic effect of porcine sera on sensitized sheep red
blood cells. Porcine sera concentration dependently induced
hemolysis of sensitized sheep red blood cells. Treatment of
porcine sera with 5 or 17 mg/mL GS1 did not attenuate
porcine sera-induced hemolysis. These data represent the
means of 3 separate experiments. No statistically significant
differences were observed.
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Porcine sera induced hemolytic assay. Sheep red blood
cells were sensitized by standard methods, as described.14
Sera dilutions of porcine sera were treated with GS1 (5 or 17
m g/mL).
Percent tissue water. The left ventricular tissues were
weighed, incubated at 110°C for 12 hours, and then weighed
again. Percent tissue water was calculated as follows: (wet
weight – dry weight)/wet weight · 100.
Drugs. Isoproterenol, acetylcholine chloride, adenosine 5´-
diphosphate, and sodium nitroprusside were obtained from
Sigma Chemical Company (St Louis, Mo). Clonidine
hydrochloride was obtained from Research Biomedicals
International (Natick, Mass). All drugs were dissolved in ultra-
pure distilled water and prepared on the day of the study. Other
reagents were obtained from the source listed in the text.
Statistical analysis. Data in the text and tables are pre-
sented as mean ± SD. The relaxation responses in the figures
are expressed as the percent relaxation of the acetylcholine
precontracted diameter (mean ± SEM) of the microvessels.
Comparisons of dose-response curves of all experimental
groups were performed by 2-way analysis of variance with
repeated measure design followed by Scheffe’s multiple com-
parison test when indicated. Comparison of hemodynamic
variables, myeloperoxidase activities, myocardial wet/dry
ratios, and gene expressions were compared with 1-way
ANOVA and Scheffe’s test post hoc with Statview 4.02
(Abacus Concepts, Inc, Berkeley, Calif). PMN GS1 antibody
effects were compared with 1-way ANOVA and Neuman-
Keuls test post hoc with Sigma Stat 2.0 (Jandel Scientific
Software, SPSS, Inc, Chicago, Ill).
Results 
Anti-C5a antibody. The monoclonal antibody, GS1,
is a murine IgG1k isotype. GS1 bound to purified pC5a
was assessed by ELISA. pC5a (100 ng/mL) -induced
porcine neutrophil (PMN) aggregation was significant-
ly inhibited by 10 mg/mL GS1 (58% ± 15% vs 15% ±
7%, respectively). GS1 inhibited pC5a (100 ng/ml) -
induced porcine PMN aggregation with an IC50 of
approximately 3 mg/mL. PAS-induced chemotaxis of
porcine PMN was concentration-dependent inhibited
by GS1. PAS-induced chemotaxis was significantly (P
= .02) inhibited by 17 mg/mL GS1 compared to
untreated PAS (0.44 ± 0.24 mm vs 0.77 ± 0.15 mm,
respectively). GS1 (17 mg/mL) failed to inhibit porcine
sera–induced hemolytic activity with sensitized sheep
red blood cells (Figs 1, 2, and 3). Plasma concentration
of GS1 during the experimental protocol was greater
than 40 m g/mL plasma (Fig 4).
Hemodynamic parameters. Although MAP, LVSP,
LV max dP/dt, and percent segmental shortening were
significantly decreased (P = .01 vs baseline for all vari-
ables) at the end of reperfusion, there was no signifi-
cant difference between the groups for any of the vari-
ables (Table I). LAD blood flow was increased after
reperfusion because of the hyperemic response and was
similar between the groups.
Microvessel characteristics. Coronary microvessels
ranged between 60 and 178 µm in internal diameter,
averaging 120 ± 9 µm in the control group and 120 ± 17
µm and 126 ± 14 µm in the saline solution and GS1
groups, respectively. Percent precontraction after the
application of acetylcholine was 50% ± 10% in the con-
trol group, and 60% ± 10% and 57% ± 17% in the saline
solution and GS1 groups, respectively. Mean concentra-
tions of acetylcholine required to obtain these percent
contractions were 1.5 ± 0.7 · 10–7 in the control group
and 1.8 ± 1.0 · 10–7 and 1.4 ± 0.7 · 10–7 mol/L in the
saline solution and GS1 groups, respectively.
Endothelium-dependent relaxation. Relaxation
responses to the receptor-mediated endothelium-
dependent vasodilator ADP were significantly reduced
in the saline solution group (P = .01 vs control; Fig 5).
The responses to ADP were preserved in the GS1
group (P = .01 vs saline solution group). Similarly,
relaxation responses to the a 2-adrenoceptor agonist
and endothelium-dependent vasodilator clonidine were
significantly reduced after cardioplegia-reperfusion (P
Fig 4. Concentration of GS1 in pig plasma during the course
of CPB. GS1 was given at 1.6 mg/mL just before the control
plasma sample was collected. Plasma samples were analyzed
by ELISA for murine IgG concentration. GS1 was main-
tained at greater than 40 m g/mL plasma throughout the exper-
imental protocol. Numbers on the X-axis represent time in
minutes during CPB and perfusion after bypass. Bars and
brackets represent means and SEM, respectively. No statisti-
cally significant differences were observed.
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= .01 vs control; Fig 6). Relaxation to clonidine was
preserved in pigs treated with the GS1 antibody.
Endothelium-independent relaxation. Relaxation
responses to sodium nitroprusside were similar in all
groups, indicating no alteration in the ability of the vas-
cular smooth muscle to relax through the cyclic guano-
sine monophosphate (Fig 7).
b -Adrenoceptor–mediated relaxation. Isoproter-
enol induced a significant relaxation in the control
microvessels. The relaxation response to isoproterenol
in the saline solution and GS1 groups were unchanged
compared with the responses of vessels from the con-
trol group (Fig 8).
Myocardial myeloperoxidase activity. Myelo-
peroxidase activity was 0.2 ± 0.2 units/g protein in the
control group, and 5.2 ± 2.7 units/g protein (P = .04 vs
control) and 0.2 ± 0.2 units/g protein, (P = .04 vs saline
solution) in the saline solution and GS1 groups, respec-
tively. This suggests a significant inhibition by GS1 of
C5a-induced neutrophil infiltration in the myocardium
after cardioplegia-reperfusion. 
cNOS and iNOS expression. The expressions of
cNOS in the saline solution group (0.32 ± 0.13, cNOS
signal density/glyceraldehyde-3-phosphate dehydroge-
nase density; P > .2) or the GS1 group (0.58 ± 0.68, P
> .2) were unchanged in the myocardium after cardio-
plegia and reperfusion compared with that in control
myocardial specimens (0.21 ± 0.16). However, iNOS
expression was increased 2-fold after cardioplegia and
2 hours of reperfusion in the saline solution group (1.03
± 0.50; P = .03) compared with that in the control
myocardium (0.41 ± 0.17). The increased expression of
Table I. Hemodynamics before and after CPB and cardioplegia-reperfusion
Saline solution GS1 antibody
30-Min 60-Min 120-Min 30-Min 60-Min 120-Min 
Baseline CPB reperfusion reperfusion Baseline CPB reperfusion reperfusion
MAP (mm Hg) 82 ± 16 49 ± 10* 44 ± 15* 40 ± 14* 85 ± 15 52 ± 7* 45 ± 9* 42 ± 6*
LVSP (mm Hg) 107 ± 27 — 77 ± 16* 58 ± 6* 112 ± 4 — 74 ± 18* 54 ± 17*
LV max dP/dt (mm Hg/sec) 1280 ± 360 — 1310 ± 566 910 ± 160* 1320 ± 230 — 1420 ± 414 910 ± 240
Percent segmental shortening 100 — 20.6 ± 20.1* 20.4 ± 16.2* 100 — 28.0 ± 29* 23.2 ± 22.7*
LAD flow (mL/min) 15 ± 5 — 31 ± 13* 21 ± 8 17 ± 5 — 30 ± 11* 25 ± 9
Data are mean ± SD.
*P = .01 versus baseline. 
Fig 5. In vitro responses of precontracted porcine coronary
microvessels to ADP from control (uninstrumented) hearts
and hearts in the saline solution and GS1 groups. Responses
are expressed as percent relaxation of acetylcholine-induced
precontraction. *P = .01 versus control and GS1 groups;
mean ± SEM.
Fig 6. In vitro responses of precontracted porcine coronary
microvessels to clonidine from control (uninstrumented)
hearts and hearts in the saline solution and GS1 groups.
Responses are expressed as percent relaxation of acetyl-
choline-induced precontraction. *P = .01 versus control and
GS1 groups; mean ± SEM.
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iNOS in the GS1 group (0.93 ± 0.91; P > .2 vs control)
was not statistically significant. There was no effect of
GS1 antibody on the expression of either isoform of
NOS. Representative blots are shown in Fig 9.
Total hemolytic complement activity CH50. The
CH50 was 0.16 ± 0.15 (concentration of sera-1) before
CPB and 0.57 ± 0.33 after 2 hours of perfusion after
CPB (P = .04 vs before CPB) in the GS1 group, com-
pared with 0.65 ± 0.36 (P = .03 vs before CPB) in the
saline solution group. There was no significant differ-
ence between the saline solution and GS1 groups at 2
hours after CPB.
Wet/dry ratio. Myocardial wet/dry ratio was 4.21 ±
0.17 in the control group, and 4.68 ± 0.34 (P = .03 vs
control) and 4.69 ± 0.24 (P = .03 vs control) in the
saline solution and GS1 groups, respectively. Although
a significant increase in myocardial water was noted
between the control and saline solution groups, GS1
did not reduce the ratio.
Discussion
The new findings of this study are that functional and
selective inhibition of C5a limits PMN-mediated
impairment of endothelium-dependent relaxation after
CPB and cardioplegia-reperfusion. This is likely due to
reduced neutrophil chemotaxis but not due to the inhi-
bition of complement activation. Despite improved
endothelial functional preservation, inhibition of C5a-
induced PMN infiltration had no effect on myocardial
functional preservation, increased expression of iNOS,
or formation of myocardial edema after 2 hours of
reperfusion after cardioplegia. Previous studies have
implicated a role of C5a in mediating some of the
myocardial ischemia-reperfusion injury in pigs and
other animals.13-15,18,19 However, pure ischemia and
ischemia under conditions of myocardial protection
and CPB may produce different cellular and biochemi-
cal injury. It is known the complement activation is
involved in alterations of vascular and myocardial
Fig 7. In vitro responses of precontracted porcine coronary
microvessels to sodium nitroprusside (SNP) from control
(uninstrumented) hearts and hearts in the saline solution and
GS1 groups. Responses are expressed as percent relaxation of
acetylcholine-induced precontraction; mean ± SEM.
Fig 8. In vitro responses of precontracted porcine coronary
microvessels to isoproterenol from control (uninstrumented)
hearts and hearts in the saline solution and GS1 groups.
Responses are expressed as percent relaxation of acetyl-
choline-induced precontraction; mean ± SEM.
Fig 9. Representative RT-PCR products of cNOS, iNOS in
porcine myocardium, shown in glyceraldehyde-3-phosphate
dehydrogenase–stained (GAPDH) 1.5% agarose gel for
amount of RNA control. Control (uninstrumented); saline
solution–treated group; GS1 antibody–treated group.
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function after ischemia or CPB.5,10,14,20 The terminal
membrane attack complex C5b-9 has a direct cytolytic
action,11,21 whereas the complement anaphylatoxin C5a
has indirect actions including increased PMN activa-
tion, chemotaxis, aggregation, and vascular plug-
ging.22,23 This may, in theory, lead to increased vascu-
lar permeability and altered endothelial function.
Endothelium-dependent relaxation of coronary
microvessels to ADP and clonidine was significantly
improved with C5a inhibition in this model of cardio-
plegia-reperfusion. The associated reduction of myelo-
peroxidase activity suggests that the reduced PMN
chemotaxis and adhesion leads to the benefical effect
on vasomotor regulation and NOS activity. Because
complement activation was not inhibited by the admin-
istration of GS1 (no change in CH50), the cytolytic and
other actions of the C5b-9 terminal membrane attack
complex may not be the only causes of endothelial
dysfunction after CPB and cardioplegia, although
C5b-9 certainly plays a role. During myocardial
ischemia, subcellular membrane fragments activate the
complement cascade24 that play an important role in
mediating reperfusion injury. Immediately after the
onset of myocardial reperfusion, the alternative com-
plement pathway is activated.18 Unlike pure myocar-
dial ischemia or cardioplegia, CPB itself activates the
alternate complement pathway. In addition, the forma-
tion of the protamine-heparin complex formation
shortly after administration of protamine potently acti-
vates the classic complement pathway.25 Thus multiple
factors lead to activation of the complement cascades
during CPB and cardioplegia, including tissue is-
chemia, contact of blood with foreign surfaces, and
pharmacologic agents. Surprisingly, myocardial func-
tion after reperfusion in our study was not improved
with administration of the GS1, as has been reported in
a myocardial infarction model using a similar mono-
clonal antibody to C5a.18 This may be due to a differ-
ence between our clinically applicable model of car-
dioplegia and other models of ischemia-reperfusion
that do not include CPB or cardioplegia. On the other
hand, these findings may suggest that the endothelium
of the coronary microvasculature is more sensitive to
the effects of C5a than is myocardial contractile func-
tion. However, it is also possible that a longer duration
of cardioplegia or reperfusion may have brought out a
beneficial functional effect of C5a inhibition. One
potential criticism of the study is that the GS1 anti-
body may not have been effective in inhibiting the
effects of C5a. However, the concentration of the GS1
used in the study clearly was sufficient to inhibit the
effects of C5a on PMN chemotaxis and aggregation.
Furthermore, GS1 reduced neutrophil infiltation in the
myocardium and improved endothelial function. Thus
lack of efficacy of the antibody was ruled out as a
cause for the failure of GS1 to improve myocardial
recovery after cardioplegia.
Because improvement of myocardial contractile
function after reperfusion was not observed, selective
inhibition of C5a did improve the impaired endotheli-
um-dependent relaxation via release of nitric oxide
from the microvascular endothelium that has been
reported previously.26 One factor potentially contribut-
ing to this may be an alteration in the expression of
cNOS, through which ADP and clonidine cause the
release of nitric oxide. Increased concentration of cir-
culating cytokines during CPB and cardioplegia may
lead to an increased expression of iNOS, which has
been implicated in causing cellular injury through
direct actions or indirectly via formation of the perox-
ynitrite free radical. In this study, expression of iNOS
was slightly increased after 1 hour of cardioplegia and
2 hours of reperfusion. It is probable that prolonged
reperfusion would lead to greater iNOS expression
because the altered expression of the iNOS gene has
been reported to require 4 or more hours in many stud-
ies. On the other hand, the expression of cNOS was not
altered after cardioplegia, nor was the cNOS expres-
sion affected by the GS1 antibody. Thus altered expres-
sion of either isoform of NOS did not contribute to
improvement in endothelium-dependent relaxation or
to the reduced infiltration of PMNs in the myocardium
as a result of GS1 administration. 
In summary, a selective inhibition of complement
fragment C5a limits PMN-mediated impairment of
endothelium-dependent relaxation after CPB and car-
dioplegia-reperfusion. Therefore the modulation of
complement has the potential to improve the recovery
of patients after cardiac operation, because of
decreased vascular permeability, improved vasomotor
regulation, and maintenance of the activity of NOS and
other homeostatic mechanisms.27 However, despite
clear inhibition of myocardial PMN infiltration and
preservation of endothelial function, GS1 had no effect
on short-term myocardial functional improvement.
We thank Jennifer M. Lee, Alvin Franklin, Dr. Jianyi Li,
and Dr. Mukesh D. Hariawala for their technical assistance
and Dr. Kalon Ho for the statistical review.
R E F E R E N C E S
1. Wachtfogel YT, Harpel PC, Edmunds LH Jr, Colman RW.
Formation of C1
s
-C1-inhibitor, kallikrein-C1-inhibitor, and plas-
min- a 2-plasmin-inhibitor complexes during cardiopulmonary
bypass. Blood 1989;73:468-71.
2. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokines
1068 Tofukuji et al The Journal of Thoracic and
Cardiovascular Surgery
December 1998
and complement levels in patients undergoing cardiopulmonary
bypass. J Thorac Cardiovasc Surg 1993;106:1008-16.
3. Kalfin RE, Engelman RM, Rousou JA, et al. Induction of inter-
leukin-8 expression during cardiopulmonary bypass. Circulation
1993;88(Suppl):II401-6.
4. Butler J, Rocker GM, Westaby S. Inflammatory response to car-
diopulmonary bypass. Ann Thorac Surg 1993;55:552-9.
5. Gillinov AM, Redmond JM, Winkelstein JA, et al. Complement
and neutrophil activation during cardiopulmonary bypass: a study
in the complement-deficient dog. Ann Thorac Surg 1994;57:345-
52.
6. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N,
Henson PM. Adherence of neutrophils to cultured human
microvascular endothelial cells: stimulation by chemotactic pep-
tides and lipid mediators and dependence upon the Mac-1, LFA-
1, p150,95 glycoprotein family. J Clin Invest 1989;83:637-46.
7. Fletcher MP, Stahl GL, Longhurst JC. C5a-induced myocardial
ischemia: role for CD18-dependent PMN localization and PMN-
platelet interactions. Am J Physiol 1993;265:H1750-61.
8. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ.
Complement proteins C5b-9 induce secretion of high molecular
weight multimers of endothelial von Willebrand factor and trans-
location of granule membrane protein GMP-140 to the cell sur-
face. J Biol Chem 1989;264:9053-60.
9. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced
expression of P-selectin in endothelial cells. J Clin Invest 1994;
94:1147-55.
10. Weisman HF, Bartow T, Leppo MK, et al. Soluble human com-
plement receptor type 1: in vivo inhibitor of complement sup-
pressing post-ischemic myocardial inflammation and necrosis.
Science 1990;249:146-51.
11. Stahl GL, Reemstra WR, Frendl G. Complement-mediated loss
of endothelium-dependent relaxation of porcine coronary arter-
ies: role of the terminal membrane attack complex. Circ Res
1995;76:575-83.
12. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and
C5b-9 generation inhibits leukocyte and platelet activation during
extracorporeal circulation. J Clin Invest 1995;96:1564-72.
13. Stahl GL, Fletcher MP, Amsterdam EA, Longhurst JC. Role of
granulocytes and C5a in myocardial response to zymosan-acti-
vated serum. Am J Physiol 1991;261:H29-37.
14. Vakeva A, Agah A, Rollins SA, Matis LA, Li L, Stahl GL.
Myocardial infarction and apoptosis after myocardial ischemia
and reperfusion: role of the terminal complement components
and inhibition by anti-C5 therapy. Circulation 1998;97:2259-67.
15. Amsterdam EA, Stahl GL, Pan H-L, Rendig SV, Fletcher MP,
Longhurst JC. Limitation of reperfusion injury by a monoclonal
antibody to C5a during myocardial infarction in pigs. Am J
Physiol 1995;268:H448-57.
16. Zhang JL, Patel JM, Block ER. Molecular cloning, characteriza-
tion and expression of a nitric oxide form porcine pulmonary
artery endothelial cells. Comp Biochem Physiol B Mol Biol
1997;116:485-91.
17. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning
and expression of inducible nitric oxide synthase from human
hepatocytes. Proc Natl Acad Sci U S A 1993;90:3491-5.
18. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP,
Longhurst JC. Limitation of reperfusion injury by a monoclonal
antibody to C5a during myocardial infarction in pigs. Am J
Physiol 1995;268:H448-57.
19. Martin SE, Chenoweth DE, Engler RL, Roth DM, Longhurst JC.
C5a decreases regional coronary blood flow and myocardial
function in pigs: implications for a granulocyte mechanism. Circ
Res 1988;63:483-91.
20. Finn A, Morgan BP, Rebuck N, et al. Effect of inhibition of com-
plement activation using recombinant soluble receptor 1 on neu-
trophil CD11b/CD18 and L-selectin expression and release of
interleukin-8 and elastase in simulated cardiopulmonary bypass.
J Thorac Cardiovasc Surg 1996;111:451-9.
21. Homeister JW, Satoh P, Lucchesi BR. Effects of complement
activation in the isolated heart: role of the terminal complement
components. Circ Res 1992;71:303-19.
22. Crawford MH, Grover FL, Kolb WP, et al. Complement and neu-
trophil activation in the pathogenesis of ischemic myocardial
injury. Circulation 1988;78:1449-58.
23. Stahl GL, Amsterdam EA, Symons JD, Longhurst JC. Role of
thromboxane A2 in the cardiovascular response to intracoronary
C5a. Circ Res 1990;66:1103-11.
24. Rossen RD, Michael LH, Kagiyama A, et al. Mechanism of com-
plement activation after coronary artery occlusion: evidence that
myocardial ischemia in dogs causes release of constituents of
myocardial subcellular origin that complex with human C1q in
vivo. Circ Res 1988;62:572-84.
25. Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of prota-
mine administration after cardiopulmonary bypass on comple-
ment, blood elements, and the hemodynamic state. Ann Thorac
Surg 1986;41:193-9.
26. Sellke FW, Shafique T, Schoen FJ, Weintraub RM. Impaired
endothelium-dependent coronary microvascular relaxation after
cold potassium cardioplegia and reperfusion. J Thorac Cardio-
vasc Surg 1993;105:52-8.
27. Sellke FW, Boyle EM, Verrier ED. Endothelial cell injury in car-
diovascular surgery: the pathophysiology of vasomotor dysfunc-
tion. Ann Thorac Surg 1996;62:1222-8.
